39 We are currently serving seven out of the top 15 global pharmaceutical companies. We are well-positioned to pursue our vision and are currently associated with the launch of six molecules, with three molecules in the commercial phase. Guided by the insights and feedback from our customers, we have embarked on a transformational journey, investing upwards of USD150 million, in enhancing operational excellence, flexible manufacturing, IT integration and advanced safety and quality systems. Our customers seek to de-risk R&D efforts and increase the speed to market of their new molecules. Working together with them in accelerating discovery, development, and manufacturing, our purpose is to realize cost efficiency, speed, responsiveness and flexibility along with scale, doing so sustainably, as a partner of choice. Sustainability in focus • Vision to support launch of 25 new medicines by 2025. • Invest in transformation of processes, infrastructure, capabilities, culture over the period between 2019 and 2023 as a part of Sai Nxt and also raise the bar on safety, quality and customer focus. • Shape our operating framework across R&D, technology transfer, and manufacturing to consistently deliver on our customer commitments with stronger governance systems and enhanced productivity and efficiency. • Perform competency profiling and risk assessment for all critical raw material suppliers. Sai Nxt: Transforming to support our customers and create value for patients Moving away from transactions to alignment and engagement Organization-wide transformation initiative currently underway with investment of > US $ 150 Mn People & Culture Expanding scientific talent pool, inducting top-notch global scientific and leadership talent, role-based integrated online training, shop floor transformation, nurturing culture of excellence. Processes & Automation Process simplification, strengthening governance systems, electronic manufacturing records, IT systems integration, foundation for seamless data capture across operations, leveraging latest technologies for innovation and intelligence. Infrastructure & Capabilities R&D expansion with wider suite of technology platforms, early phase delivery facility, flexible manufacturing with 2.5x capacity, advanced safety & quality systems. USD millions FY22 FY21 FY20 FY19 FY18 47 62 115 140 154 increase in net fixed assets over 4 years 3x
RkJQdWJsaXNoZXIy MTIwMDc4NQ==